What Does Early Carotid Plaque Mean? (TRT Q&As)
Timeline
The member says his cardiologist found very early cholesterol buildup in the carotid artery without significant blockage. Dr. O’Connor emphasizes controlling the ABCDs™, particularly blood pressure and LDL cholesterol, and discusses more advanced coronary imaging such as CT angiography to better define cardiovascular risk.
The member notices that his estimated GFR is lower than when he was younger despite still being within the expected range. Dr. O’Connor explains that creatinine-based eGFR is only an estimate and says an eGFR of 82 with otherwise reassuring findings does not indicate kidney disease in this case.
The member has coronary artery disease, recurrent kidney stones, prior lithotripsy, and a recent creatinine of about 1.8. Dr. O’Connor explains that muscle mass and creatine can distort creatinine-based eGFR, but given the member’s kidney stone history and hypertension he recommends proper kidney evaluation, including proteinuria testing and consultation with a nephrologist.
A 65-year-old member on TRT with a prior LAD blockage and coronary stent asks about adding Anavar or Masteron. Dr. O’Connor discusses their potential effects on cholesterol, cardiovascular health, hair, prostate, and other risk factors and emphasizes that existing coronary disease makes additional anabolic steroid exposure more concerning.
The member has reduced his testosterone dose to about 200 mg and asks whether adding Deca or NPP could help chronic joint problems from heavy lifting. Dr. O’Connor acknowledges reports of improved joint symptoms with nandrolone but also discusses concerns about cardiovascular effects and the possibility that anabolic steroids may adversely affect tendons and other soft tissues.
A 38-year-old man on long-term testosterone says his cardiologist agreed to an echocardiogram but does not favor calcium scoring. Dr. O’Connor explains that an echocardiogram evaluates heart structure and function rather than coronary plaque and discusses calcium scoring and newer CT coronary angiography as ways to assess coronary artery disease.
Video Summary
This session addresses a range of questions that come up in real-world hormone and metabolic care. Rather than treating any single number as definitive, the discussion emphasizes lab-centered decision-making that integrates symptoms, history, and repeatable trends. Viewers get a clear sense of how clinicians prioritize stability and follow-up when uncertainty is high.
Several segments focus on how and when to adjust a plan, including dosing choices, monitoring cadence, and symptom tracking. The conversation highlights common misinterpretations that lead to unnecessary changes, and it explains what would justify reassessment. Practical framing is provided so patients can bring better questions to follow-up visits.
Risk and prevention themes also appear throughout, including cardiometabolic markers and long-term health planning. The session reinforces that individualized care depends on context, goals, and tolerability, not rigid rules. Overall, the episode provides a structured way to think about next steps without losing sight of long-term outcomes.
Drug Callouts
Condition Callouts
Key Takeaways
- Lab trends over time are more informative than single measurements when symptoms are stable.
- Reference ranges help, but decisions still depend on individual context and goals.
- Follow-up timing should be planned to answer a specific clinical question, not to chase reassurance.
- Clear symptom tracking makes lab interpretation more actionable and less reactive.
- Measured observation can be the safest choice when risk is low and uncertainty is high.